Digitisation | April 08, 2026
IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Subscribe To Our Newsletter & Stay Updated
